PMID- 32100113
OWN - NLM
STAT- MEDLINE
DCOM- 20210129
LR  - 20210129
IS  - 1432-1262 (Electronic)
IS  - 0179-1958 (Linking)
VI  - 35
IP  - 5
DP  - 2020 May
TI  - Effect of metformin on the mortality of colorectal cancer patients with T2DM: 
      meta-analysis of sex differences.
PG  - 827-835
LID - 10.1007/s00384-020-03539-5 [doi]
AB  - PURPOSE: To evaluate the effect of metformin as a treatment for the mortality of 
      colorectal cancer (CRC) patients with type 2 diabetes mellitus (T2DM). METHODS: 
      We searched Medline, PubMed, EMBASE, Clinical Trials.gov 
      (http://www.clinicaltrials.gov), and the Cochrane Collaboration Library from 
      inception to November 2019. To analyze the relationship between metformin and the 
      overall mortality, specific mortality, and sex differences in CRC patients with 
      T2DM, hazard ratios (HRs) with 95% confidence intervals (CIs) were used. Egger's 
      test and Begg's test were used to assess publication bias. RESULTS: We included 8 
      cohort studies in our meta-analysis. CRC patients with T2DM treated with 
      metformin had a lower overall mortality than CRC patients with T2DM who did not 
      receive metformin (HR = 0.80, 95% CI 0.67-0.95). There was no significant 
      difference in CRC-specific mortality between CRC patients with T2DM who used 
      metformin and those who did not (HR = 0.84, 95% CI 0.65-1.08). However, females 
      had a lower CRC-specific mortality among CRC patients with T2DM than males 
      (HR = 0.63, 95% CI 0.41-0.97). CONCLUSION: Metformin reduced the overall 
      mortality of CRC patients with T2DM. Moreover, female CRC patients with T2DM 
      using metformin had lower CRC-specific mortality than male CRC patients with 
      T2DM.
FAU - Wang, Yunzi
AU  - Wang Y
AD  - Department of Pathology, Sichuan Science City Hospital, Mianyang, 621000, 
      Sichuan, China.
FAU - Xiao, Jingping
AU  - Xiao J
AUID- ORCID: 0000-0002-6623-1253
AD  - Department of Pharmacy, The Third Hospital of Mianyang, Sichuan Mental Health 
      Center, Mianyang, 621000, Sichuan, China. xiaojingping5@126.com.
FAU - Zhao, Yuanyu
AU  - Zhao Y
AD  - Department of Pathology, Sichuan Science City Hospital, Mianyang, 621000, 
      Sichuan, China.
FAU - Du, Shijuan
AU  - Du S
AD  - Department of Pathology, Sichuan Science City Hospital, Mianyang, 621000, 
      Sichuan, China.
FAU - Du, Jiang
AU  - Du J
AD  - Department of General Surgery, Sichuan Science City Hospital, Mianyang, 621000, 
      Sichuan, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20200225
PL  - Germany
TA  - Int J Colorectal Dis
JT  - International journal of colorectal disease
JID - 8607899
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Aged
MH  - Cohort Studies
MH  - Colorectal Neoplasms/*complications/*mortality
MH  - Diabetes Mellitus, Type 2/*complications/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Metformin/*therapeutic use
MH  - Middle Aged
MH  - Publication Bias
MH  - *Sex Characteristics
OTO - NOTNLM
OT  - Colorectal cancer
OT  - Meta-analysis
OT  - Metformin
OT  - Mortality
OT  - Sex difference
OT  - T2DM
EDAT- 2020/02/27 06:00
MHDA- 2021/01/30 06:00
CRDT- 2020/02/27 06:00
PHST- 2020/02/13 00:00 [accepted]
PHST- 2020/02/27 06:00 [pubmed]
PHST- 2021/01/30 06:00 [medline]
PHST- 2020/02/27 06:00 [entrez]
AID - 10.1007/s00384-020-03539-5 [pii]
AID - 10.1007/s00384-020-03539-5 [doi]
PST - ppublish
SO  - Int J Colorectal Dis. 2020 May;35(5):827-835. doi: 10.1007/s00384-020-03539-5. 
      Epub 2020 Feb 25.